Related Experiment Videos
Moclobemide for depression: an Australian psychiatric practice study
J W Tiller1, G F Johnson, G D Burrows
1Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Victoria, Australia.
Journal of Clinical Psychopharmacology
|August 1, 1995
Summary
Moclobemide effectively treated major depression in 712 patients, with 65% showing moderate improvement. This real-world study found moclobemide well-tolerated, with most adverse events mild and short-lived.
Area of Science:
- Psychiatry
- Clinical Pharmacology
Background:
- Major depression is a prevalent mental health condition requiring effective treatment.
- Real-world studies are crucial to understand antidepressant efficacy and tolerability beyond controlled trials.
- Moclobemide, a reversible inhibitor of monoamine oxidase A, offers a treatment option for depression.
Purpose of the Study:
- To evaluate the efficacy and tolerability of moclobemide in a large, unselected patient population with major depression.
- To assess treatment outcomes in routine psychiatric practice.
Main Methods:
- A total of 712 patients diagnosed with major depression received moclobemide treatment.
- Patients were treated in ordinary psychiatric practices, including both outpatients and inpatients.
- Data collected included patient demographics, treatment history, adverse events, concomitant medications, and physician global impression.
Main Results:
- 65% of patients showed moderate improvement or better after 8 weeks of moclobemide treatment.
- 52% of patients reported no adverse events; common events included insomnia, nausea, and headache, mostly mild and transient.
- Concomitant medication use in 73% of patients did not result in adverse interactions.
Conclusions:
- Moclobemide demonstrates significant efficacy and good tolerability in the routine treatment of major depression.
- The drug is effective in a broad patient population, including those with prior treatment failures or comorbidities.
- Real-world data support moclobemide as a valuable therapeutic option for major depressive disorder.